{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:46:34Z","timestamp":1784648794735,"version":"3.55.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":179,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This proof-of-concept, cross-sectional study assessed the feasibility and clinical relevance of detecting circulating tumor DNA (ctDNA) and RNA (ctRNA) in plasma of patients with thyroid cancer. The analysis was performed concurrently with clinical and biochemical assessment to explore its value as a complementary tool for postoperative surveillance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-four patients whose primary tumors had been molecularly profiled for key driver mutations and gene fusions were enrolled. Using a tumor-informed strategy, digital PCR assays were designed to detect patient-specific alterations in matched plasma ctDNA and ctRNA collected between 2021 and 2023. Molecular findings were correlated with treatment response categories according to the 2015 American Thyroid Association (ATA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ctDNA and\/or ctRNA were detected in all patients with a structurally incomplete response, showing full concordance with imaging findings. In contrast, 91% of patients with an excellent response had undetectable ctDNA\/ctRNA, consistent with remission. Among those with indeterminate and biochemical incomplete response group, results were variable: one patient with undetectable Tg exhibited an ETV6::NTRK3 fusion in cfRNA, while two of three with biochemical incomplete response tested negative for ctDNA\/ctRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This cross-sectional analysis demonstrated that liquid biopsy accurately reflected disease activity and showed strong concordance with primary tumor alterations. These findings support its feasibility and clinical potential as an adjunct to conventional monitoring, particularly when Tg measurement or tumor tissue availability is limited. Prospective longitudinal studies are warranted to validate its role in personalized postoperative surveillance of thyroid cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0255","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:42:58Z","timestamp":1766158978000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":2,"title":["Tumor-informed liquid biopsy for monitoring thyroid cancer: a proof-of-concept study"],"prefix":"10.1530","volume":"15","author":[{"given":"Debora Mota Dias","family":"Thomaz","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7395-3342","authenticated-orcid":true,"given":"Welbert Gomes","family":"Rocha","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Cavallari","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline de Oliveira Ribeiro","family":"Viana","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Maranh\u00e3o Fagundes","family":"Velloni","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Elen Costa da Silva","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Alberto","family":"Curioni","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano Mesquita","family":"Callegari","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Roberto Maciel","family":"Martins","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Paula","family":"Mello Biscolla","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0156-8274","authenticated-orcid":true,"given":"Janete Maria","family":"Cerutti","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026070714013295000_bib1","first-page":"10","article-title":"Cancer Statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026070714013295000_bib2","article-title":"Global cancer observatory [Internet]","author":"International Agency for Research on Cancer","year":"2025"},{"key":"2026070714013295000_bib3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714013295000_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070714013295000_bib5","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1210\/jc.2013-1072","article-title":"Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma","volume":"98","author":"Pupilli","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714013295000_bib6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fonc.2019.01510","article-title":"Non-invasive molecular detection of minimal residual disease in papillary thyroid cancer patients","volume":"9","author":"Almubarak","year":"2020","journal-title":"Front Oncol"},{"key":"2026070714013295000_bib7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s12020-020-02526-8","article-title":"The role of a new polyclonal competitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer with structural disease but low levels of serum thyroglobulin by immunometric and LC-MS\/MS methods","volume":"72","author":"Guastapaglia","year":"2021","journal-title":"Endocrine"},{"key":"2026070714013295000_bib8","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1210\/jc.2011-1740","article-title":"Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714013295000_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-015-0660-4","article-title":"Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma","volume":"51","author":"Shen","year":"2016","journal-title":"Endocrine"},{"key":"2026070714013295000_bib10","first-page":"67","article-title":"The value of serum thyreoglobulin levels and whole body (I-131) scintigraphy in the follow-up of the thyroid cancer patients after thyroidectomy","volume":"36","author":"Ku\u010dukali\u0107-Selimovi\u0107","year":"2012","journal-title":"Coll Antropol"},{"key":"2026070714013295000_bib11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2265.2011.04278.x","article-title":"Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal","volume":"76","author":"Cherk","year":"2012","journal-title":"Clin Endocrinol"},{"key":"2026070714013295000_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00259-008-0789-y","article-title":"Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning","volume":"35","author":"Caballero-Calabuig","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070714013295000_bib13","first-page":"1473","article-title":"Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning","volume":"46","author":"Ma","year":"2005","journal-title":"J Nucl Med"},{"key":"2026070714013295000_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14740\/jem940","article-title":"Multiple metastatic lesions on a post-ablative whole-body scan despite a negative serum thyroglobulin level in a patient with papillary thyroid cancer","volume":"14","author":"Kim","year":"2024","journal-title":"J Endocrinol Metab"},{"key":"2026070714013295000_bib15","first-page":"249","article-title":"Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer \u2013 Clinical Considerations","volume":"57","author":"Prpi\u0107","year":"2018","journal-title":"Acta Clin Croat"},{"key":"2026070714013295000_bib16","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026070714013295000_bib17","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1210\/jc.2009-1349","article-title":"Mutant BRAFT1799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status","volume":"94","author":"Cradic","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714013295000_bib18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.biopha.2013.06.007","article-title":"Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAFV600E: a non-invasive tool panel for early detection of thyroid cancer","volume":"67","author":"Zane","year":"2013","journal-title":"Biomed Pharmacother"},{"key":"2026070714013295000_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hed.21178","article-title":"Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas","volume":"32","author":"Chuang","year":"2010","journal-title":"Head Neck"},{"key":"2026070714013295000_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1530\/EJE-17-0499","article-title":"ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population","volume":"178","author":"Bastos","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"2026070714013295000_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27707","article-title":"AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma","volume":"66","author":"Sisdelli","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"2026070714013295000_bib22","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1530\/EC-19-0459","article-title":"Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior","volume":"8","author":"Paniza","year":"2019","journal-title":"Endocr Connect"},{"key":"2026070714013295000_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.643151","article-title":"Advances in detecting low prevalence somatic TERT promoter mutations in papillary thyroid carcinoma","volume":"12","author":"da Costa","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070714013295000_bib24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1590\/S0004-27302012000900010","article-title":"Development, characterization and clinical validation of new sensitive immunofluorometric assay for the measurement of serum thyroglobulin","volume":"56","author":"Nakabashi","year":"2012","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2026070714013295000_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00173","article-title":"Circulating BRAFV600E cell-free DNA as a biomarker in the management of anaplastic thyroid carcinoma","volume":"2","author":"Iyer","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026070714013295000_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/8909224","article-title":"Detection of circulating tumor DNA in patients with thyroid nodules","volume":"2021","author":"Patel","year":"2021","journal-title":"Int J Endocrinol"},{"key":"2026070714013295000_bib27","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/cas.14389","article-title":"Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis","volume":"111","author":"Lan","year":"2020","journal-title":"Cancer Sci"},{"key":"2026070714013295000_bib28","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1089\/thy.2021.0267","article-title":"Circulating tumor DNA harboring the BRAFV600E mutation may predict poor outcomes of primary papillary thyroid cancer patients","volume":"31","author":"Sato","year":"2021","journal-title":"Thyroid"},{"key":"2026070714013295000_bib29","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/thy.2020.0296","article-title":"Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma","volume":"31","author":"Qin","year":"2021","journal-title":"Thyroid"},{"key":"2026070714013295000_bib30","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.3390\/jcm9082481","article-title":"Detection of BRAFV600E in liquid biopsy from patients with papillary thyroid cancer is associated with tumor aggressiveness and response to therapy","volume":"9","author":"Jensen","year":"2020","journal-title":"J Clin Med"},{"key":"2026070714013295000_bib31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jmoldx.2015.08.003","article-title":"Detection of circulating BRAFV600E in patients with papillary thyroid carcinoma","volume":"18","author":"Lubitz","year":"2016","journal-title":"J Mol Diagn"},{"key":"2026070714013295000_bib32","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/hed.23195","article-title":"Study of peripheral BRAFV600E mutation as a possible novel marker for papillary thyroid carcinomas","volume":"35","author":"Kwak","year":"2013","journal-title":"Head Neck"},{"key":"2026070714013295000_bib33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12020-022-03004-z","article-title":"Ultrasensitive detection of BRAFV600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer","volume":"76","author":"Gouda","year":"2022","journal-title":"Endocrine"},{"key":"2026070714013295000_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2018.08.013","article-title":"Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer","volume":"103","author":"Allin","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026070714013295000_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/thy.2016.0076","article-title":"Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma","volume":"27","author":"Sandulache","year":"2017","journal-title":"Thyroid"},{"key":"2026070714013295000_bib36","first-page":"3389","article-title":"Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma","volume":"18","author":"Li","year":"2019","journal-title":"Exp Ther Med"},{"key":"2026070714013295000_bib37","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hed.25155","article-title":"Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma","volume":"40","author":"Condello","year":"2018","journal-title":"Head Neck"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/1\/ETJ-25-0255.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/1\/ETJ-25-0255.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0255\/508597\/etj-25-0255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0255\/508597\/etj-25-0255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:40Z","timestamp":1783447300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/1\/ETJ250255\/75654\/Tumor-informed-liquid-biopsy-for-monitoring"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0255","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"article-number":"ETJ250255"}}